AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
IOPROMIDE
42 registrations across 11 African markets— 33 active
Markets with IOPROMIDE
🇿🇦South Africa
12 registrations
12 active
🇲🇦Morocco
6 registrations
6 active
🇹🇳Tunisia
5 registrations
0 active
🇨🇮Côte d'Ivoire
4 registrations
0 active
🇬🇭Ghana
4 registrations
4 active
🇹🇿Tanzania
3 registrations
3 active
🇺🇬Uganda
2 registrations
2 active
🇰🇪Kenya
2 registrations
2 active
🇿🇼Zimbabwe
2 registrations
2 active
🇳🇬Nigeria
1 registration
1 active
🇿🇲Zambia
1 registration
1 active
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| ULTRAVIST 300 Solution For Injection/Infusion | 🇰🇪Kenya | Bayer Pharma AG | active | Feb 2031 |
| ULTRAVIST 370 Solution For Injection/Infusion | 🇰🇪Kenya | Bayer Pharma AG | active | Feb 2031 |
| ULTRAVIST SOLUTION FOR INJECTION (Each ml contains Iopromide 370) | 🇬🇭Ghana | BAYER WEST CENTRAL AFRICA SA; 72Q9+93P, ABIDJAN, CÔTE D’IVOIRE | active | Aug 2030 |
| ULTRAVIST SOLUTION FOR INJECTION (Each ml contains Iopromide 370) | 🇬🇭Ghana | BAYER WEST CENTRAL AFRICA SA; 72Q9+93P, ABIDJAN, CÔTE D’IVOIRE | active | Aug 2030 |
| Ultravist 300 Injection Solution for Injection | 🇿🇲Zambia | Bayer (Pty) Ltd | active | Jul 2030 |
| ULTRAVIST 370mg SOLUTION FOR INJECTION | 🇬🇭Ghana | — | active | Jul 2030 |
| ULTRAVIST 370mg SOLUTION FOR INJECTION | 🇬🇭Ghana | — | active | Jul 2030 |
| ULTRAVIST 300 INJECTABLE; INJECTION | 🇿🇼Zimbabwe | BAYER (PTY) LTD | active | Dec 2027 |
| ULTRAVIST 370 INJECTABLE; INJECTION | 🇿🇼Zimbabwe | BAYER (PTY) LTD | active | Dec 2027 |
| ULTRAVIST 300MG/ 100 ML SOLUTION AQUEUSE POUR INJECTABLEION FLACON DE 100ML | 🇨🇮Côte d'Ivoire | BAYER WEST & CENTRAL AFRICA | expired | Jan 2026 |
| ULTRAVIST-370 370MG SOLUTION INJECTABLE IV FLACON DE 100ML | 🇨🇮Côte d'Ivoire | BAYER WEST & CENTRAL AFRICA | expired | Jan 2026 |
| ULTRAVIST-370 370MG SOLUTION INJECTABLE IV FLACON DE 50ML | 🇨🇮Côte d'Ivoire | BAYER WEST & CENTRAL AFRICA | expired | Jan 2026 |
| ULTRAVIST-300 300MG SOLUTION INJECTABLE IV FLACON DE 50ML | 🇨🇮Côte d'Ivoire | BAYER WEST & CENTRAL AFRICA | expired | Jan 2021 |
| ULTRAVIST 370 Solution injectable / 370mg d'iode/ml | 🇹🇳Tunisia | BAYER AG | expired | Aug 2009 |
| ULTRAVIST 370 Solution injectable / 370mg d'iode/ml | 🇹🇳Tunisia | BAYER AG | expired | Aug 2009 |
| ULTRAVIST 300 Solution injectable / 300 mg d'iode/ml | 🇹🇳Tunisia | BAYER AG | expired | Aug 2009 |
| ULTRAVIST 300 Solution injectable / 300mg d'iode/ml | 🇹🇳Tunisia | BAYER AG | expired | Aug 2009 |
| ULTRAVIST 300 Solution injectable / 300 mg d'iode/ml | 🇹🇳Tunisia | BAYER AG | expired | Aug 2009 |
| ULTRAVIST 370 125 ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 300 500 ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 370 500 ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 300 100ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 300 20ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 300 200 ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 370 50ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 300 50ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 300 75 ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 370 200 ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 300 125 ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| ULTRAVIST 370 100ml | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
| Ultravist 370 Solution | 🇹🇿Tanzania | Bayer East Africa Ltd | active | — |
| IOPROMIDE PARENTERAL
ORDINARY VIALS | 🇺🇬Uganda | BAYER SCHERING PHARMA | active | — |
| ULTRAVIST SOLUTION INJECTABLE | 🇲🇦Morocco | — | active | — |
| ULTRAVIST SOLUTION INJECTABLE | 🇲🇦Morocco | — | active | — |
| ULTRAVIST SOLUTION INJECTABLE | 🇲🇦Morocco | — | active | — |
| ULTRAVIST SOLUTION INJECTABLE | 🇲🇦Morocco | — | active | — |
| ULTRAVIST SOLUTION INJECTABLE | 🇲🇦Morocco | — | active | — |
| Ultravist Injectable Solution | 🇹🇿Tanzania | Bayer East Africa Ltd | active | — |
| Ultravist Injectable Solution | 🇹🇿Tanzania | Bayer East Africa Ltd | active | — |
| Ultravist 370 Injection Solution for injection/infusion | 🇳🇬Nigeria | — | active | — |
| IOPROMIDE PARENTERAL
ORDINARY VIALS | 🇺🇬Uganda | BAYER SCHERING PHARMA | active | — |
| ULTRAVIST SOLUTION INJECTABLE | 🇲🇦Morocco | — | active | — |
IOPROMIDE in Africa — Regulatory Overview
IOPROMIDE is registered across 11 African markets with 42 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Morocco, Tunisia, Côte d'Ivoire and 7 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 42 registrations, 33 (79%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.